Author

Armand Bankhead

Fred Hutch Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1 Assay:whole-exome sequencing· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Bruce MontgomeryiD· 2 shared Colin C. PritchardiD· 2 shared Colm M. MorrisseyiD· 2 shared Gavin HaiD· 2 shared Ilsa M. ColemaniD· 2 shared Navonil De SarkariD· 2 shared Peter S. NelsoniD· 2 shared Anai KthariiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

Bruce MontgomeryORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Moving Beyond Binary Biomarkers: Machine Learning Model Resolves Concurrent and Molecularly Heterogeneous Mismatch Repair and Homologous Recombination Deficiencies in Prostate Cancer

Komal Sharma, Divin A. Wilson, Yu Wang, Shabi Haider, Vineel Bhatlapenumarthi, Daniel Boiarsky, John M. Cipriaso, Leo Yermakov, Raja Ram Dutta, Manavita Vashisth, Ilsa M. Coleman, Armand Bankhead, Shantanu K. Jadhav, Bhabishya Neupane, Bradley W. Taylor, , Navonil De Sarkar

This paper develops a machine learning model to identify molecularly distinct DDR subgroups in prostate cancer, revealing concurrent repair deficiencies and improving therapeutic stratification.

bioRxiv · Oct 8, 2025 · PreprintGenomics

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

Sander B. Frank, Thomas W. Persse, I. M. Coleman, Armand Bankhead, Dapei Li, Navonil De Sarkar, Divin Wilson, Dmytro Rudoy, Manasvita Vashisth, Patty Galipeau, Michael Yang, Brian P. Hanratty, Ruth F. Dumpit, Colm M. Morrissey, Eva Corey, , Peter S. Nelson

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

bioRxiv · Jul 16, 2024 · PreprintCancer Biology